Home
>
US Stocks
>
Relmada Therapeutics Inc
Relmada Therapeutics Inc
RLMD

Relmada Therapeutics Inc (RLMD)

$23.90.97%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
23.38
Today Low/High
23.28 / 23.9
52 Week Low/High
$20.6 / $40.87
Market Cap
$416.21M

Company Details

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.
Organisation
Relmada Therapeutics Inc
Headquaters
New York, New York, US
Employees
14
Industry
Pharmaceuticals: Major
CEO
Sergio Traversa

Discover more

Frequently Asked Questions

What is Relmada Therapeutics Inc (RLMD) share price today?

Can Indians buy Relmada Therapeutics Inc (RLMD) shares?

How can I buy Relmada Therapeutics Inc (RLMD) shares from India?

Can Fractional shares of Relmada Therapeutics Inc (RLMD) be purchased?

What are the documents required to start investing in Relmada Therapeutics Inc (RLMD) stocks?

We are a SEBI registered investement advisor